Park Ha Biological Technology stock rises on upcoming ticker symbol change
Investing.com - UBS raised its price target on Northrop Grumman (NYSE:NOC) to $770.00 from $769.00 while maintaining a Buy rating on the defense contractor’s stock. The aerospace giant, with a market capitalization of $85.6 billion and an impressive 29% price return over the past six months, continues to attract analyst attention. According to InvestingPro data, five analysts have recently revised their earnings expectations upward for the upcoming period.
The firm cited Northrop’s strong multi-year growth outlook from its existing portfolio, even before considering potential upside from B-21 reconciliation and repricing, a possible F/A-XX win, and Golden Dome exposure.
UBS noted that Northrop has taken a "prudently conservative outlook" on these outcomes, while demonstrating another quarter of strong margin execution and a mid-single-digit starting point for 2026 revenue guidance.
The investment bank identified three programs—B-21, F/A-XX, and Golden Dome—as potential near-term catalysts for the stock that could contribute to greater than the 11% free cash flow per share compound annual growth rate UBS models through 2029.
UBS believes Northrop Grumman is well-positioned to benefit from durable defense spending priorities with long-term growth visibility, despite a slight reduction in 2025 revenue expectations due to timing factors. For deeper insights into NOC’s valuation and growth prospects, including 12 additional exclusive ProTips and comprehensive financial analysis, visit InvestingPro.
In other recent news, Northrop Grumman Corporation reported its third-quarter 2025 earnings, delivering an impressive earnings per share (EPS) of $7.67. This figure exceeded analyst expectations of $6.46, resulting in an 18.73% earnings surprise. However, the company’s revenue did not meet forecasts, totaling $10.42 billion against the anticipated $10.71 billion. Despite the strong EPS performance, the revenue shortfall reflects varied investor reactions. These developments are significant for investors assessing the company’s financial health and potential future performance. Analyst firms may provide further insights into these results in the coming weeks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.